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Overactive bladder syndrome negatively aﬀects the daily life of many people. First-line conservative treatments, such as
antimuscarinics, do not always lead to suﬃcient improvement of the complaints and/or are often associated with disabling adverse
eﬀectsleadingtotreatmentfailure.Electricalstimulationofthesacralnerveshasemergedasanalternativeandattractivetreatment
for refractory cases of bladder overactivity. Few theories attempted to explain its mechanism of action which remains elusive. It
involves percutaneous posterior tibial nerve stimulation and more commonly sacral neuromodulation. For the latter, temporary
sacral nerve stimulation is the ﬁrst step. If the test stimulation is successful, a permanent device is implanted. The procedure is safe
andreversible.Itcarriesadurablesuccessrate.Thetechniqueshouldbecombinedwithcarefulfollowupandattentiveadjustments
of the stimulation parameters in order to optimize the clinical outcomes. This paper provides a review on the indications, possible
mechanismsofaction,surgicalaspectsandpossiblecomplications,andsafetyissuesofthistechnique.Theeﬃcacyofthetechnique
is also addressed.
1.Introduction
Overactive bladder (OAB) also referred to as the urgency-
frequency syndrome, with or without urge urinary inconti-
nence, can considerably impair the patient’s quality of life.
It is widely accepted that diet and life style modiﬁcations,
behavioural therapy, and medication belong to the stan-
dard conservative therapeutic options and are considered
as ﬁrst-line measures. The International Consultation on
Incontinence (ICI) guidelines states that when the ﬁrst-
line approach is not fully satisfactory or fails after 8–12
weeks, alternative therapies should be sought out [1]. It is
worthwhile and justiﬁed to proceed to second-line therapy
if patients are refractory to antimuscarinic therapy or if the
treatment is contraindicated. Second-line therapies include
less invasive measures such as detrusor injections with
botulinumtoxin(BTX)andsacralneuromodulation (SNM),
whereas more invasive measures constitute surgical tech-
niques, for example, bladder augmentation or substitution.
Pelvic neuromodulation has been proven eﬀective and is
today an established treatment option for patients refractory
to or intolerant of conservative treatments. It involves
percutaneous posterior tibial nerve stimulation (PTNS) and
more commonly SNM. This paper provides a contemporary
overview of pelvic neuromodulation addressing mechanism
of action, surgical and technical aspects, and safety and
clinical outcomes with special emphasis on SNM.
2. ElectricalNeuromodulation
In the settings of OAB, electrical neuromodulation devices
act to modulate detrusor contractions. The use of neuro-
modulation is based on the knowledge that urge inconti-
nence usually results from an imbalance of inhibitory and
excitatory control systems, often causing a “hyperactive”
detrusor, leading to incontinence during the ﬁlling phase
[2]. In 1977, Teague and Merrill transrectally stimulated
the pudendal nerve electrically in dogs which was found
to activate pudendal-to-pelvic nerve reﬂex that depresses
or eliminates uninhibited detrusor contractions [3]. Tai
et al. were able to show the eﬀectiveness of S2 sacral spinal2 Advances in Urology
cord microstimulation with a single electrode to induce
prominentbladderandurethralsphincterresponsesinspinal
cord-injured cats demonstrating the potential for using
microstimulationtechniquestomodulatelowerurinarytract
function in patients with neurogenic voiding dysfunctions
[4]. Another publication by the same group showed that
in anesthetized chronic spinal cord-injured cats, impaired
storage and voiding functions of the lower urinary tract
couldbeimprovedbyactivationofthesomaticaﬀerentpath-
ways in the pudendal nerve [5]. The authors demonstrated
that electrical stimulation of the pudendal nerve at 3Hz
inhibited nonvoiding contractions during bladder ﬁlling,
suppressed reﬂex voiding, and increased bladder capacity.
In a human study, data of 22 patients with OAB, who
underwent an ambulant urodynamic investigations (ACM)
before and during SNM, were investigated by Scheepens et
al. [6]. Blind analysis of the ACM was performed, and the
detrusor activity index (DAI) was calculated as the degree of
detrusor overactivity. The subjective as well as the objective
results showed a decrease in bladder overactivity during
SNM. During SNM, instabilities of bladder were still present;
however, bladder overactivity was reduced. A signiﬁcant
c o r r e l a t i o nw a sf o u n di nD A Ir e d u c t i o no ft h eA C Mb e f o r e
and during SNM as compared to the clinical improvement
on OAB symptoms.
This concept has become popular since it bridges the
gap between conservative treatment and highly invasive
options. Currently, these devices include SNM via surgically
implanted electrodes and newer methods that deliver percu-
taneous stimulation of the peripheral tibial nerve. The exact
mechanism of action is not well understood. A number of
theories have been proposed to explain the eﬀect of electrical
neuromodulation which can be summarized as follows.
(i) In human subjects, it was shown that sensory input
through the pudendal nerve inhibited detrusor activ-
ity and, therefore, pudendal nerve stimulation and
enhancement of external sphincter tone may serve
to control bladder overactivity and facilitate urine
storage [7].
(ii) The bladder tends to respond to neural stimulation
initially with rapid contraction followed by slow,
longer-lasting relaxation. With recurrent, repetitive
stimuli produced by the electrical stimulation, there
is a decay and downregulation of the bladder’s
response, thus reducing the detrusor muscle overac-
tivity [8].
(iii) Stimulation of aﬀerent sacral nerves in either the
pelvis or lower extremities increases the inhibitory
stimuli to the eﬀerent pelvic nerve and reduces
detrusor contractility. One theory is that there is
supraspinal inhibition of the detrusor [2]. Another
assumption is that, at low bladder volumes, there
is stimulation of the hypogastric nerve through
activation of sympathetic ﬁbers and at maximal
bladder volume direct stimulation of the pudendal
nerve nuclei in the spinal cord [9, 10].
(iv) It is assumed that neuromodulation aﬀects the
“neuroaxis” at various levels and restores the bal-
ance between excitatory and inhibitory regulation at
various locations within the peripheral and central
nervous system [11].
2.1. Percutaneous Posterior Tibial Nerve Stimulation (PTNS).
PTNS is a minimally invasive, oﬃce-based procedure that
involves percutaneous placement of a 34-gauge (ga) needle
over the medial malleolus of the ankle with subchronic
electrical stimulation of the posterior tibial nerve. The
procedure is a 30-minute treatment session administered
over a period of 12 weeks. Another method that has been
described is implanting the device in the same area as
well [12]. The procedure utilizes the peroneal nerve for
transcutaneous access to the S3 spinal cord region.
PTNS has shown some promise in the treatment of
patients with refractory urge incontinence. McGuire et al.
originally reported the ﬁrst study applying PTNS in 1983
[13]. Of 22 patients with urge incontinence, 55% were cured
and 32% improved. Earlier data with PTNS show excellent
success rates with approximately 50% of patients showing
some response with few complications noticed, albeit in
low-quality studies [14]. Recently, Yoong et al. described
a shortened 6-week treatment protocol with PTNS in 43
women with refractory OAB [15]. The authors showed
a signiﬁcant reduction in symptoms and improvement in
health-related quality of life suggesting that the duration of
treatment can be halved compared with the conventional
12 weeks, which would make it more acceptable and cost
eﬀective for patients. In a slightly older study from Turkey,
Kabay et al. demonstrated that 12 weeks of PTNS was
eﬀective to suppress neurogenic detrusor overactivity in 19
multiple sclerosis patients [16]. Although this is a promising
technology, the results of one multicenter randomized trial
of 100 patients with OAB symptoms did not show a reduced
rate of urinary frequency when PTNS was compared to
tolterodine extended release, 4mg daily [17]. The technique
is likely to have limited applicability due to response
durability since it requires regularly applying a stimulus with
a percutaneous needle.
2.2. Sacral Neuromodulation (SNM). SNM uses mild elec-
trical pulses to activate or inhibit neural reﬂexes by con-
tinuously stimulating the sacral nerves that innervate the
pelvic ﬂoor and lower urinary tract; it is also referred to as
the pacemaker for the bladder. The technique was pioneered
by Schmidt et al. at the University of California in San
Francisco who introduced it in 1979 [18]. This was followed
by further solidity by the same investigators in the mid-
1980s [19, 20]. From the ﬁrst experimental use of SNM
in dogs, InterStimTM therapy was developed by Medtronic
(Minneapolis, Minn, USA) for use in humans. This therapy
employs an implanted unilateral lead stimulating the S3
nerve root that is attached to a small pacemaker placed
within a subdermal pocket in the buttock region. It is
FDA approved for refractory urge incontinence, refractory
urgency frequency, and idiopathic nonobstructive urinaryAdvances in Urology 3
retention. For application in OAB, the ICI level of rec-
ommendation is grade A for women and B for men [1].
The technique has been also used for conditions such as
interstitial cystitis and pelvic pain syndrome. InterStim ther-
apy has continuously evolved in terms of knowledge of
its mode of action as well as in technical and surgical
aspects. During the early stages of SNM, the permanent lead
placement was secured by fascial ﬁxation with the patient
under general anaesthesia. However, Spinelli at al. developed
a reﬁned ﬁxation method with twist locks or silicone anchors
allowed a smaller incision under conscious sedation and,
as such, a less invasive approach [21]. To further improve
the technical features of the lead, Spinelli et al. designed a
self-anchoring tined lead which compromises four sets of
silicone tines proximal to the electrodes as an integral part
of the lead body, with each tine element consisting of four
ﬂexible, pliant tines [22]. The system engages subcutaneous
tissue,particularlymuscletissue, todecreaseaxialmovement
of the lead and consequent dislodgment of the stimu-
lating electrodes. The tined lead obtained FDA approval
in 2002 and opened gates for widespread application of
SNM.
Preprocedure patient counselling is critical in reassuring
the patient and managing treatment expectations. Once it
has been decided that the patient is an appropriate candidate
for InterStim therapy, implantation proceeds in 2 steps: a
test phase and implantation or lead removal based on test
response. The initial test phase can be performed in the
oﬃce or operating room allowing for placement of the
lead with a test period of 1 to 2 weeks; full implanta-
tion can be performed under local or general anesthesia.
Patients are counselled that approximately 60% of patients
undergoing oﬃce-based test stimulation and 70% under-
going operating room-based test stimulation will have a
positive test response [23]. Response is objectively evaluated
by pre- and postvoiding diaries assessing various urinary
parameters.
2.2.1. One-Stage Implant. In the 1990s, Schmidt et al.
devised a simple outpatient diagnostic test that involved
percutaneous placement of a wire to stimulate the S3 nerve
root and evaluate motor and sensory responses [24]. The
innovative technique allowed for subchronic S3 nerve root
stimulation, and this peripheral nerve evaluation (PNE)
served as the basis for future clinical applications of SNM.
In PNE, an insulated thin wire is placed into the third
sacral nerve (S3) foramen in the vicinity of S3 with the
patient under local anesthesia while placed on a table in
the prone position. In our center, we utilize 1% plain
lidocaine. The surgeon must make sure not to inject the
local anesthetic into the foramen since this may lead to
numbness of the underlying nerves that can preclude the
desired sensory response. Thesciatic notchescanbe palpated
either uni- or bilaterally. The S3 foramen can be found one
ﬁngerbreadth oﬀ the midline at the level of the sciatic notch.
The procedure is done bilaterally, and the side giving better
response is chosen. Responses signalling correct placement
include bellows contraction of the pelvic ﬂoor and plantar
ﬂexion of the great toe. With the in-oﬃce test stimulation,
the patient will also be able to conﬁrm correct placement
with contraction or tingling of the pelvic ﬂoor muscles (e.g.,
rectum, vagina, scrotum, and perineum). S2 placement will
demonstrate plantar ﬂexion of the entire foot with lateral
rotation,whereasS4placementwillrevealnolowerextremity
movement despite bellows response. Once the appropriate
side and position selected, the temporary unipolar lead is
connected to an external neurostimulator (external pulse
generator) and taped to the skin surface. This procedure may
be facilitated by the availability of oﬃce-based ﬂuoroscopy.
Response is assessed by pre- and postprocedure voiding
diaries. Patients who respond favorably and demonstrate
a 50% symptom improvement from baseline proceed to
removal of the temporary lead followed by implantation of
a quadripolar permanent lead and implantable neurostimu-
lator placement. The leads are easily removed in the oﬃce
once the test phase is complete, typically in 5 to 7 days.
The duration of this test is limited to a maximum of 2
weeks because longer implantation of the temporary lead
may increase the probability of bacterial contamination of
the test stimulation lead [25]. Signiﬁcant restrictions, such
as no showering and decreased activities, also dictate short-
term testing. Ideal candidates should not be obese, should
have OAB without voiding dysfunction, and should not have
any signiﬁcant coexisting medical conditions that would
make an oﬃce-based procedure diﬃcult [23]. In addition,
patients with previous sacral or coccygeal scar may not be
ideal candidates since this may preclude localization and
placement of the any components of the temporarily device.
Limitations of this approach include migration of the
temporary wires and a suboptimal test phase, as well as
the potential discrepancy in clinical response when the
permanentquadripolar leadisimplanted. Short-termtesting
period as well as the lead migration probably explain the
relatively low success rate of PNE, estimated at around 50%
[26, 27]. Another observation is that to 33% of the patients
who have a beneﬁcial test stimulation with a temporary
lead do not continue to have a successful outcome after
the INS is implanted or, in other words, are false-positive
responders [28]. Exchange of leads during the one-stage
implant procedure may contribute to therapy failure during
followup [29]. On the other hand, some patients who do not
respond to PNE may in fact have an excellent outcome when
the permanent electrode and neurostimulator/implantable
pulse generator (IPG) are implanted [30]. Lead migration is
considered the main factor leading to false-negative results
[28].
2.2.2. Two-Stage Implant. If the patient is not a candidate
for oﬃce-based test stimulation or did not respond to the
in-oﬃce test, test stimulation may be performed in the
operating room (OR). Furthermore, the shift from PNE
(one-stage implant) to a two-stage procedure helps to min-
imize technical-related failures and increase test eﬃcacy and
patient selection. Immediate implantation of a permanent
lead aims to avoid lead migration and allows prolonged
patient testing/screening [31, 32].4 Advances in Urology
This procedure is similar to the oﬃce-based test but
involves tined quadripolar leads, thus improving lead ﬁxa-
tion and test response, and can be performed using intra-
venous (IV) sedation, local anaesthesia, or general anaesthe-
sia. In case general anaesthesia is used, the anaesthetist is
reminded to avoid using any long-acting muscle relaxants
that may impair the ability to stimulate the sacral nerves
or visualize their motor response. Fluoroscopy with C-arm
should be utilized to facilitate placement. Once the right or
left S3 foramen has been identiﬁed and subsequently chosen,
the permanent tined lead is passed through the foramen
needle. The lead is then exposed and tested in the 0, 1, 2,
and 3 positions for response. Then, the sheath is carefully
removed so as not to move the lead and expansion of the
tines ﬁx the lead in place. The lead is then tunnelled deeply
through the subcutaneous fat to a position in the right
or left buttock depending on the patient’s dominant hand
side where the permanent implantable pulse generator (IPG)
will be placed eventually during the second stage. The lead
is attached to the temporary connector and then tunneled
through the subcutaneous fat to an alternative exit site.
This is particularly an important step because if the patient
were to get a superﬁcial skin infection, then alternative exit
site would help prevent the infection from spreading to the
location of the permanent IPG and back to the lead [23].
Finally, the lead is connected to an external pulse generator
and taped to the skin surface. A 7- to 14-day subchronic
home test period is used to determine which patients meet
criteria to have the IPG implanted. At the end of the test
period,thepatientreturnstotheORforeitherremovalofthe
lead or implantation of the IPG, depending on the subjective
and objective responses.
A prospective, randomized study showed that the two-
stage implant technique of SNM has a higher success rate
compared to the one-stage method, despite prior positive
PNE, both in the short term and in the long term [28].
Another important study by Borawski et al. randomized 17
patients to staged implant and 13 patients to PNE [26]. The
stagedimplantgroupwassigniﬁcantlymorelikelytoproceed
to IPG implant than the PNE group (88% versus 46%).
Similar results were shown by Peters et al. who also noted
that sensory response assessment at the time of implantation
reduced the reoperation rate from 43% to 0% [27]. In
addition, increased response rate to SNM was noted when
the testing period was extended from 5 to 7 days to 14 days
per implanted electrode lead [31]. The costs for the test
protocol with the tined leads are much higher compared to
the PNE test. Currently, the use of either one of the two
screening options is arbitrary.
2.2.3. Implantation. After a successful test phase, the patient
is brought to the OR for implantation of the implantable
generator (IPG). If the ﬁrst test stimulation was oﬃce
based, ﬂuoroscopy is required to place the permanent lead.
The quadripolar tined lead is inserted in a similar fashion
on the side where the patient had the best in-oﬃce test
response. The lead is then tunnelled deeply through the
subcutaneous fat to an incision in the right or left buttock
region. It is attached to the IPG and buried in the deep
subcutaneous pocket. On the other hand, if the ﬁrst phase
was done in the OR and there is pre-existing placement
of the permanent quadripolar lead, the implant stage is
quick, does not require ﬂuoroscopy, and can be performed
under local or general anaesthesia. The previous incision
where the temporary connector was placed in the buttock is
opened,andthepermanentIPGisthenconnectedtothelead
and buried in a deep subcutaneous pocket in the buttock.
Buttock placement of the IPG has become an attractive
alternative to subcutaneous implant in the lower part of
the anterior abdominal wall because of the lower incidence
of adverse events (approximately 2-fold), shorter operation
time, and avoidance of patient repositioning during the
operation[33].Postoperatively,theIPGisswitchedon,andit
is programmed with diﬀerent electrodes mapping to give the
patient a comfortable electrical stimulation. Patients need
lifelongsurveillancetomanagedevice-relatedissuesthatmay
arise.
2.2.4. Complications, Safety, and Clinical Results. The very
nature of this mode of therapy mandates a 100% reop-
eration to replace the IPG at some point due to the
limited longevity of the neurostimulator. Adverse events are
usually related to the implant procedure and the presence
of the implant or of undesirable stimulation. The most
common adverse events include lead migration, implant
site pain, bowel dysfunction, and infection. The majority of
adverse events do not require surgical intervention. Potential
lead migration can be simply resolved without signiﬁcant
morbidity in the majority of patients by reprogramming,
reinforcing the lead, or inserting a new lead contralaterally
[34]. Some patients lose beneﬁt due to accommodation
to the stimulation, but contralateral placement can be
attempted to overcome this [35]. If infection is superﬁcial,
the usual management is antibiotics; however, if there is
a deep infection that is not resolved with oral or IV
antibiotics, then explantation of the neurostimulator is
required. In case of adverse stimulation, it is commonly
suﬃcient to change the stimulation factors (e.g., electrode
mapping, pulse width, amplitude, mode, or polarity). Hijaz
et al. reported a review of complication management and
implant troubleshooting strategy from the Cleveland Clinic
database of 214 tine lead implants [36]. One hundred
and sixty-one patients (75.5%) proceeded to placement
of the IPG. Seventeen patients (10.5%) had the device
completely removed for infection and failure of clinical
response. Twenty-six patients (16.1%) underwent device
revision due to attenuation of response, infection, pain at
IPG site, and lead migration. The majority of patients with
revision due to poor response had abnormal impedance
measurements, with equalization of impedance in 2 leads
being the most common ﬁnding. As a result, the authors
strongly advocate IPG interrogation with impedance testing
to completely evaluate patients with response-related dys-
function.
Contraindications for the patient with an implanted
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ortherapeuticultrasounddiathermy.Thediathermy’senergy
can be transferred through the implant and could be
harmful. MRI is not recommended. Nevertheless, Elkelini
and Hassouna reported on six patients with implanted sacral
nerve stimulator who underwent eight MRI examinations
at 1.5Tesla conducted in areas outside the pelvis [37]. IPGs
were examined before and after MRI procedures. All patients
had their parameters recorded; then the IPGs were put
to “nominal” status. Patients were monitored continuously
during and after the procedure. During the MRI session,
no patient showed symptoms that required stopping the
examination. There was no change in perception of the stim-
ulation after reprogramming of the implanted sacral nerve
stimulator, according to patients’ feedback. Devices were
functioning properly, and no change in bladder functions
was reported after MRI examinations. Another safety issue
with SNM has been its eﬀect in pregnant women and the
developing fetuses. Wiseman and colleagues have addressed
this issue by examining 6 eligible patients having SNM sacral
who subsequently achieved pregnancy [38]. In 5 patients,
the stimulator was deactivated between weeks 3 and 9 of
gestation, after which 2 with a history of urinary retention
had urinary tract infection. In another case, stimulation
was discontinued 2 weeks before conception. The only
noted complication developed in a pregnancy in which
birth was premature at 34 weeks. Three patients underwent
normal vaginal delivery, including 1 in whom subsequent
implant reactivation did not resolve voiding dysfunction. In
3cases,electivecesareansectionwasperformed.Allneonates
were healthy. The authors concluded that when a patient
on neuromodulation achieves pregnancy, the stimulation
should be deactivated. If implant deactivation leads to
urinary-related complications that threaten the pregnancy,
reactivation should be considered. Elective cesarean section
should be considered since it is possible for sacral lead
damage or displacement to occur during vaginal deliv-
ery.
Several investigators have attempted to identify parame-
ters that have predictive value in selecting the best candidates
and those patients most likely to beneﬁt from SNM therapy.
Amundsen at al. reported that age >55 years and more than
threechronicconditionswereindependentfactorsassociated
withalowercurerateinpatientsimplantedwithasacralneu-
romodulatorforrefractoryurgeincontinence[39].Theyalso
noted that a neurologic condition may be associated with a
decreaseinthecurerate.Shermanetal.showedthatevidence
of pelvic muscle activity and test stimulation performed
within 4 years were predictive factors of a positive response
[40]. Other studies have demonstrated that patients with
OAB symptoms and concomitant emotional disorders are
far more likely to respond poorly to test stimulation, have
symptom recrudescence following permanent implant, and
haveahigherincidenceofreoperations[28,41].Inadiﬀerent
study, Foster et al. showed that the reduction in 24-hour
pad weightbest predicted long-termpatient satisfaction with
SNM therapy [42].
There is convincing evidence for the success of SNM
with the Interstim technique for refractory OAB. Several
studies including RCTs and long-term observational studies
reported fair clinical response between 64 and 88% of all
patients [43]. All parameters investigated showed signiﬁcant
improvement compared to the placebo group: a 23–46%
decrease in the number of voids per day, 44–77% increase in
theaveragevoidedvolume,56–90%decreaseinincontinence
episodes per day, 64–100% decrease in pads, and 39%
increase in maximum cystometric capacity [36, 41, 44–49].
Cappellano et al. showed a signiﬁcant improvement in the
quality of life score in patients with urgency incontinence
whounderwentSNM[50].Whenfollowedupfor18months,
they were asked whether they would undergo this treatment
again. 90% responded yes and 100% would recommend it to
arelativeorfriend.Recently,Chartier-Kastleretal.published
amulticenterprospectiveobservationaltrialevaluatinglong-
term eﬀectiveness of SNM in patients with a permanent
implant (2003–2009) [51]. Clinical improvement of greater
than or equal to 50% was seen in 447/527 patients with
OABat12monthsfollowup.Clinicalimprovementremained
relatively stable up to 60 months. Median patient satisfaction
with treatment was between 60 and 80%. In another
study, Leong et al. surveyed all patients who received SNM
between 1990 and 2007 by mailing a questionnaire regarding
satisfaction and experiences with the system [52]. Of the 275
questionnaires sent, 207 were returned for a 75% response
rate. Treatment was done for OAB in 55% of the patients.
Overall satisfaction with SNM was high at 90%.
Recently,severaltechnicalaspectsofSNMwithInterStim
therapy led to the development of the InterStim II system,
whichreceived regulatory approvalin Europe and theUnited
States in 2006. InterStim II eliminates the need for extension
cables and is almost 50% lighter and smaller in volume
compared to the initial model. Subsequently, this allows for
a smaller incision and smaller pocket to be created and thus
less patient discomfort with higher patient acceptance which
is of particular importance for skinny patients. However, the
above-mentioned advantages come with the expense of a
shorter battery life. Most new implanted IPGs are supplied
with small iCon patient programmers, oﬀering the patients
the possibility to choose from up to four preset programs,
provided better control of stimulation by the patient. Other
available SNM technology includes the twin-chamber IPGs
that can feed two electrodes providing synergetic eﬀect.
3. Conclusions
Electrical neuromodulation devices act to modulate detrusor
contractions. Currently, these devices include SNM and
PTNS. SNM is an eﬀective treatment modality for patients
with refractory OAB and should be oﬀered before applying
more invasive, irreversible treatments. The procedure is
safe and minimally invasive involving one or two-stage
implantation. It carries small, treatable, and nonpermanent
side eﬀects. Although the mechanisms behind its action are
still not fully understood, the therapy has been shown to be
eﬀective in the long term. Followup should include regular
checks to determine eﬃcacy of the therapy and a review
of the electrical system. The SNM technology continues to
evolve.6 Advances in Urology
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